drug
LETROZOLE
Marketedupdated 6mo agoby Yiling Pharmaceutical Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(9)
approval · 9
Jun 3, 2011
approval
LETROZOLE — FDA approval
LETROZOLE
→
May 15, 2012
approval
LETROZOLE — FDA approval
LETROZOLE
→
Jul 19, 2014
approval
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
LETROZOLE — FDA approval
LETROZOLE
→
Trials studying LETROZOLE
- phase1A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- phase2A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
- phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase1A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
- phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- phase3A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 17, 2027
304 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Apr 14, 2036formulationUS 10799506
- Apr 14, 2036formulationUS 12064434
- Apr 14, 2036formulationUS 12419894
- Aug 7, 2034method-of-use (U-3998)US 12544380
- Nov 9, 2031compositionUS 91937325.0y
- Nov 9, 2031method-of-use (U-3264)US 98687395.0y
- Mar 13, 2031compositionUS 84153554.3y
- May 25, 2030compositionUS 86859803.5y
- Dec 9, 2029method-of-use (U-3264)US 89626303.1y
- Aug 20, 2029method-of-use (U-3264)US 94161362.8y
- Jun 17, 2028compositionUS 83242251.6y
FDA exclusivities (1)
- Sep 17, 2027I-951Indication (3y)304d
News(3)
- Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeRestricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.stat · 6mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 6mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 6mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that